A Dark Vector Cognition product

Item 4. Controls and Procedures

3K characters. Original on sec.gov · Markdown

Item 4. Controls and Procedures

Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of the end of the period covered by this quarterly report (the Evaluation Date). Based on such evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of the Evaluation Date, the Company’s disclosure controls and procedures are effective.

Changes in Internal Control Over Financial Reporting

There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) during the first fiscal quarter of 2025 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

**Item 2.**Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

During the first three months of 2025, the Parent Company repurchased shares of its common stock as follows:

PeriodTotal Number of Shares PurchasedAverage Price Paid Per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsMaximum Number of Shares that May Yet Be Purchased Under the Plans or Programs
January 1 - January 312,698,784$104.832,698,78444,618,770
February 1 - February 283,230,149104.372,835,98041,782,790
March 1 - March 312,965,821108.232,961,98138,820,809
Total8,894,754(1)$105.808,496,74538,820,809(2)

(1) During the first three months of 2025, 398,009 shares were purchased in connection with income tax withholding obligations related to the vesting of restricted-share-based awards during the period.

(2) The total remaining shares available for purchase at March 31, 2025, are related to a 100,000,000 share repurchase authorization by the board of directors announced in November 2022.

Previous: Item 3. Quantitative and Qualitative Disclosures about Market Risk · Next: Item 5. Other Information